Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP-Kinase inhibition against BRAF mutated melanoma
Ontology highlight
ABSTRACT: Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP-Kinase inhibition against BRAF mutated melanoma
PROVIDER: PRJNA1119558 | ENA |
REPOSITORIES: ENA
ACCESS DATA